Cellular Longevity, Inc. Seto) eos CN eM a)o 4 The first consumer animal pharma company. We have a drug that will extend dog lifespan by 1-4 years.MOVING FAST: what we've done since the Series Seed (Jan 2020) Poached Regeneron’s ($678 Big Pharma) Head of Aging Found a drug and showed it works in dogs Went from solo-founder to team of 8 Demonstrated >$8K willingness-to-pay for product Will be in companion dogs 1 year earlier than projected at Seed Cleared significant regulatory hurdles Moonshot biology on tech timescalesOver 15,000 years, dogs were selectively bred to be our protectors, partners, and best friends. We turned the wolf into the chihuahua, the Siberian Husky, and the poodle. This caused health issues.The biggest issue: big dogs age 2x faster Bis pe | 2] oo me 2 1“ Great Dane Mastiff Irish Wolfhound Bloodhound £10 Bo 2 .e 8 a5 s ; 7 YEAR MEAN LIFESPAN —_ 0 SCC 4 ‘Average adult male body mass (ko) a ‘Be Inverse correlation between 5 ha Ye lifespan and size of dog : > Chihuahua Schipperke Lhasa Apso Toy Poodle 16 YEAR MEAN LIFESPANAbnormally high levels of IGF-1 accelerates dog aging - a genetic mistake caused by dog inbreeding 7x Higher IGF-1 Low IGF-1 Short lifespan Long lifespan (~7 years) ‘da (-16 years) * Bloodhound Toy PoodleOur first product safely lowers IGF-1 by 55% . & 55% reduction in IGF- 1 r oa Increase lifespan } (4+ years) My cS ‘= Gas Great Dane English Springer Spaniel 7 year median 12 year median lifespan lifespan 1187 ng/mL IGF-1 31025 ng IGFPet Parents are desperate to have more years with their pets - and will pay for them. $8,117 (mean) and $5,000 (median) WTP >70% margin with scale 1,511 waitlist sign ups in 3 weeks w/ ~$5 CPA “My dogs are my kids. I’d do anything for them.” Diane F, pet parent “Greater than 95 percent of clients will pay over $1000 per year.” Dr. Shanna Landy, Veterinarian at Hillside Veterinary ClinicAnimal Pharma is a historically stodgy industry untouched by consumer trends* Opportunity to build a consumer brand with patent protection “Why? High barrier of entry: the expertise & context necessary to build a therapeutics company rarely overlaps with the expertise or inclination to run a consumer-facing brand. Plus, consumer-matketing a cancer drug would be tacky - but you can build a brand around a drug that augments health.Few middlemen = simple go-to-market Human Pharma Co Government Phar Medicaid i Ho: Human patient Coleviity. Dog owner direct-to-consumer relationship possibleDogs-first is the fastest way to get the world’s first longevity drug on market & break the longevity barrier* *a demonstration of lifespan extension that proves to the masses that aging can be slowedOur strategy: reformulated human generic medicines Why: Low technical risk Very safe for dogs Patent protected Cheap drugs with established supply chain Fastest go-to-market Almost no R&D spendFast go-to-market with reformulated generic drugs, then we'll build our own TODAY 2-4 YEARS 7+ YEARS Generic drugs Proprietary + partnered Proprietary drugs + reformulated drugs partnered drugs Dogs only Dogs only Dogs & humans [| $$ + dataWe can get to market with $20M Cost to bring a human drug to market: $500M-$IB+ MILESTONE Now 4:20 avai qr22 CUMULATIVE CAPITAL REQUIREDFew could build this re Celine Halioua Dr. Aruna Perera Pounder CEO Head of CMC DeDiaAustINDaamond. “Br frances chen, vp, Aging Biology (consult-to-hire) __,2usrezSainas_— HeacofGonsumer DVM PAD. Venture Partner at Founded Regeneron's Developed multiple Operations "Sicdee Longevity Fund, ($67B pharma) Aging drug products, Oxford Ph.D. drop-out, “Group, brought currently Director of technical founder multiple drugs to clinic CMC at Progenity THE LONGEVITY FUND Hanne: REGENERON = PFOGEN ty” ovectas Sharma Project Management Ww. Associate Scientist VALEANT ‘@) OXFORD Shaina Sovel Taylor DF. TYler Mequade Special Adisr, Operators TechnologyThe time to build this company BIOLOGICAL NEW MARKET REGULATORY DERISKING DYNAMICS LOOSENING Decades of validated Large & growing, Sept 2019 creation of longevity biology 4 price-insensitive Pet + accelerated ready to translate Parents market regulatory pathwaySeries Seed Jan 2020 RRC) Bea oli ses ey oa eens ee eomec teat Me merc First Round Capital/Josh Kopelman The Longevity Fund/Laure Deming BoxGroup/Greg Rosen ewes ys ECs] Seed extension to: e@ Get into clinic with dog lifespan drug e Demonstrate improvement of dog health e Develop second pipeline product (osteoarthritis drug) e Build out consumer team, branding, & positioning e Extend runway into 2022The dogs say thanks! celine@celevity.coAppendixThis is the fastest way to longevity drugs See it work on a venture-relevant timescale We know if our drug works before we invest in clinical development Lighter animal regulation means we can get to market & revenue quickly Test the drug what it is meant to do, not forKey Differences: Human vs. Vet Med cost TIME TILL... FIRST SIGN THAT LIFESPAN PRECLINICAL, CLINICAL OUR DRUG WoRKS MARKETS READOUT IN TARGET SPECIES CANINES, $5mM $3M 6 2-3 3-5 Human Pharma months years years $iim —-$15-$500m + St 812+ 15-40+Our lead drug is currently available as a 2X/day shot. We will reformulate it into a 1x/year. Why we are confident our drug can be formulated into a 1-year implant cheaply: it's been done before with nearly identical drugs. IMPLANT FORMULATION C > deslorelin ($$$) + hydrogenated palm oil (s) * lecithin (s) + sodium {acetate anhydrous (s) J Modeling our implant off of SUPRELORIN Equivalent experience to getting a microchip. 6 months duration - ¢73 each 12 months duration - £146 each 23mm long soft ror scutaneous (under skin) _J Vatidates abiity tomanufacture product cheaplyPricing Breakdown at moderate scale a) col gust 1 ear ose we $150 $35 $5 $70 $120 $620 drug tuly diagnostic ne alivet visits *cust prof formulated egnostic incl support $5K upfront - 5 shots (all in) insurancelis CHC $750 $35 | $25 | $250 $500 $3,445 Sxdrug fully diagnostic incl allvet visits* profit formulated Postage cust support $10K upfront - 5 shots (all in) $8,445 profit $1K - 1year Cy¥S/ eee lia) $5K - 5 shots 68% margin $10K - 5 shots 84% marginOverview of Celevity Pipeline Dog lifespan extension Common dog diseases CANINES IGF-1 reduction Klotho upregulation OA secondary to Hip Dysplasia Teeter ome el ce Mass-market follow-onSecond Product: Osteoarthritis 39% of supplements market for joints $1.32B spend on limb+joint dysfunction 1of 5 dogs affected by OA in their lifespan Diagnosis increased 66% in the last 10 years Impacts both large and small dogs Very obvious to dog owner: impaired mobility, pain, swelling senescent cell healthy joint accumulation (OA) OA joint w senolytic HIP DYSPLASIA & OSTEOARTHRITISGantt - Top Two Dog Products DOG LIFESPAN EXTENSION Doc OSTEOARTHRITIS 2020 June July Aug Sept Oct Nov Dec Detar Det PeeQ3 Goals - Full Speed Product development cLy-001 1. Begin long-release formulation with CROs 2. Read out beagle dose optimization - confirm unit economies dose 3. Kick off heaithspan study in aged beagles (6 month study ~ will read out in Q4) 4. Kick off mouse lifespan study (mult-year study) Second drug 1. Finalize which of our drugs willbe the final drug. For that drug 2. Show POC in laboratory beagles 3, Scope out dosing/safety study for kick off in a4 Diagnostic 1. Solidfy sciencelmechanism for IGF1 diagnostic 2. Manufacturing pipeline, CRO for dx (not signed just validated/understood) 3. Maybe: full consumer-triendly packaging Go-to-market, regulation, and consumer Branding 1. Complete brand development, style guide, voice 2. New company name and logo if appropriate 3. New website that is consumer-triendly 4. Continue regular conversations with dog owners and vets Regulation 1. Fee waiver petition fled 2 Full scientific argument document for the CVM 3. Fitst draft indication N=4 trials 4.10 dogs signed for the 2 Raise between $1M and $3M from dog owners 3. Fitst dog dosed with Octreotide 4. Develop biomarker tracking mechanism trial Team & Ops 4, Hire a Director of Pharma Proj Management 2. Hire Research Associate